These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 20210571)

  • 1. Dipeptidyl peptidase-IV inhibitors are efficient adjunct therapy in HNF1A maturity-onset diabetes of the young patients--report of two cases.
    Katra B; Klupa T; Skupien J; Szopa M; Nowak N; Borowiec M; Kozek E; Malecki MT
    Diabetes Technol Ther; 2010 Apr; 12(4):313-6. PubMed ID: 20210571
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Meglitinide analogues in adolescent patients with HNF1A-MODY (MODY 3).
    Becker M; Galler A; Raile K
    Pediatrics; 2014 Mar; 133(3):e775-9. PubMed ID: 24567025
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.
    Hermansen K; Kipnes M; Luo E; Fanurik D; Khatami H; Stein P;
    Diabetes Obes Metab; 2007 Sep; 9(5):733-45. PubMed ID: 17593236
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antidiabetic effects of dipeptidyl peptidase-IV inhibitors and sulfonylureas in streptozotocin-nicotinamide-induced mildly diabetic mice.
    Matsuyama-Yokono A; Tahara A; Nakano R; Someya Y; Shiraki K; Hayakawa M; Shibasaki M
    Metabolism; 2009 Mar; 58(3):379-86. PubMed ID: 19217455
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of young patients with HNF1A mutations (HNF1A-MODY).
    Raile K; Schober E; Konrad K; Thon A; Grulich-Henn J; Meissner T; Wölfle J; Scheuing N; Holl RW;
    Diabet Med; 2015 Apr; 32(4):526-30. PubMed ID: 25483937
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Complementing insulin therapy to achieve glycemic control.
    Barnett AH
    Adv Ther; 2013 Jun; 30(6):557-76. PubMed ID: 23797471
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metformin + saxagliptin for type 2 diabetes.
    Scheen AJ
    Expert Opin Pharmacother; 2012 Jan; 13(1):139-46. PubMed ID: 22149373
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Significance of combination therapy with an insulin sensitizer and a DPP-4(dipeptidyl peptidase-4) inhibitor].
    Yasuda T; Shimomura I
    Nihon Rinsho; 2013 Mar; 71(3):555-62. PubMed ID: 23631252
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Second line therapy: type 2 diabetic subjects failing on metformin GLP-1/DPP-IV inhibitors versus sulphonylurea/insulin: for GLP-1/DPP-IV inhibitors.
    Kumar A
    Diabetes Metab Res Rev; 2012 Dec; 28 Suppl 2():21-5. PubMed ID: 23280862
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Beneficial effects of vildagliptin combined with miglitol on glucose tolerance and islet morphology in diet-controlled db/db mice.
    Ishibashi K; Hara A; Fujitani Y; Uchida T; Komiya K; Tamaki M; Abe H; Ogihara T; Kanazawa A; Kawamori R; Watada H
    Biochem Biophys Res Commun; 2013 Nov; 440(4):570-5. PubMed ID: 24103756
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination therapy of dipeptidyl peptidase-4 inhibitors and metformin in type 2 diabetes: rationale and evidence.
    Liu Y; Hong T
    Diabetes Obes Metab; 2014 Feb; 16(2):111-7. PubMed ID: 23668534
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination therapy with DPP-4 inhibitors and insulin in patients with type 2 diabetes mellitus: what is the evidence?
    Charbonnel B; Schweizer A; Dejager S
    Hosp Pract (1995); 2013 Apr; 41(2):93-107. PubMed ID: 23680741
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of HNF1A-MODY and HNF4A-MODY in Irish families: phenotypic characteristics and therapeutic implications.
    Kyithar MP; Bacon S; Pannu KK; Rizvi SR; Colclough K; Ellard S; Byrne MM
    Diabetes Metab; 2011 Dec; 37(6):512-9. PubMed ID: 21683639
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Post-transplantation diabetes mellitus: evaluation of treatment strategies.
    Haidinger M; Antlanger M; Kopecky C; Kovarik JJ; Säemann MD; Werzowa J
    Clin Transplant; 2015 May; 29(5):415-24. PubMed ID: 25777150
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of dipeptidyl peptidase-4 inhibitors in combination with metformin.
    Fass AD; Gershman JA
    Adv Ther; 2013 Apr; 30(4):337-53. PubMed ID: 23605247
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical use of dipeptidyl peptidase-4 and sodium-glucose cotransporter 2 inhibitors in combination therapy for type 2 diabetes mellitus.
    Guthrie RM
    Postgrad Med; 2015 Jun; 127(5):463-79. PubMed ID: 25956345
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Response to multiple glucose-lowering agents in a sib-pair with a novel HNF1α (MODY3) variant.
    Tan CSH; Ang SF; Lim SC
    Eur J Hum Genet; 2020 Apr; 28(4):518-520. PubMed ID: 31844173
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis.
    Deacon CF; Mannucci E; Ahrén B
    Diabetes Obes Metab; 2012 Aug; 14(8):762-7. PubMed ID: 22471248
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sitagliptin, a dipeptidyl peptidase-IV inhibitor, improves psoriasis.
    Nishioka T; Shinohara M; Tanimoto N; Kumagai C; Hashimoto K
    Dermatology; 2012; 224(1):20-1. PubMed ID: 22056790
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Homozygous Hypomorphic
    Misra S; Hassanali N; Bennett AJ; Juszczak A; Caswell R; Colclough K; Valabhji J; Ellard S; Oliver NS; Gloyn AL
    Diabetes Care; 2020 Apr; 43(4):909-912. PubMed ID: 32001615
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.